Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 7, 2018
Credit Suisse27th Annual Healthcare Conference on Tuesday, November 13, 2018at 2:50 p.m. MST( 4:50 p.m. ET) in Scottsdale, AZ Evercore ISI HealthConX Conferenceon Wednesday, November 28, 2018at 4:35 p.m. ETin Boston, MA
Both presentations will be given by Apellis founder and chief executive officer
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials such as the results reported in this release will be indicative of results that will be generated in future clinical trials; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of such clinical trials will warrant regulatory submissions and whether APL-2 will receive approval from the
Source: Apellis Pharmaceuticals, Inc.